Articles from DBV Technologies S.A.
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
AMF Regulated InformationChâtillon, France, January 13, 2025
By DBV Technologies S.A. · Via GlobeNewswire · January 13, 2025
DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study
Châtillon, France, January 8th, 2025
By DBV Technologies S.A. · Via GlobeNewswire · January 8, 2025
DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old
Châtillon, France, December 11th, 2024
By DBV Technologies S.A. · Via GlobeNewswire · December 11, 2024
Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2024
Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2024
By DBV Technologies S.A. · Via GlobeNewswire · December 2, 2024
DBV Technologies Announces Plan to Implement ADS Ratio Change
Châtillon, France, November 11, 2024
By DBV Technologies S.A. · Via GlobeNewswire · November 11, 2024
DBV Technologies Reports Third Quarter 2024 Financial Results
Châtillon, France, November 6, 2024
By DBV Technologies S.A. · Via GlobeNewswire · November 6, 2024
DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe
Châtillon, France, October 22, 2024
By DBV Technologies S.A. · Via GlobeNewswire · October 22, 2024
DBV Technologies to Participate in Upcoming ACAAI 2024 Congress
Châtillon, France, October 18, 2024
By DBV Technologies S.A. · Via GlobeNewswire · October 18, 2024
Information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2024
Information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2024
By DBV Technologies S.A. · Via GlobeNewswire · October 14, 2024
DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial
Châtillon, France, September 23, 2024
By DBV Technologies S.A. · Via GlobeNewswire · September 23, 2024
DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Châtillon, France, September 4, 2024
By DBV Technologies S.A. · Via GlobeNewswire · September 4, 2024
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024
By DBV Technologies S.A. · Via GlobeNewswire · August 2, 2024
DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report
Châtillon, France, July 30, 2024
By DBV Technologies S.A. · Via GlobeNewswire · July 30, 2024
DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results
Châtillon, France, July 30, 2024
By DBV Technologies S.A. · Via GlobeNewswire · July 30, 2024
DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024
Châtillon, France, July 29, 2024
By DBV Technologies S.A. · Via GlobeNewswire · July 29, 2024
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
AMF Regulated InformationMontrouge, France, July 8, 2024
By DBV Technologies S.A. · Via GlobeNewswire · July 8, 2024
DBV Technologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Châtillon, France, June 5, 2024
By DBV Technologies S.A. · Via GlobeNewswire · June 5, 2024
Information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2024
Information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2024
By DBV Technologies S.A. · Via GlobeNewswire · June 4, 2024
DBV Technologies Announces Plan to Implement ADS Ratio Change
Châtillon, France, May 31, 2024
By DBV Technologies S.A. · Via GlobeNewswire · May 31, 2024
DBV Technologies to Participate in Upcoming EAACI 2024 Congress
Châtillon, France, May 30, 2024
By DBV Technologies S.A. · Via GlobeNewswire · May 30, 2024
DBV Technologies Announces Plan to Implement ADS Ratio Change
Châtillon, France, May 17, 2024
By DBV Technologies S.A. · Via GlobeNewswire · May 17, 2024
DBV Technologies Announces Results of its 2024 Combined General Meeting
Châtillon, France, May 16, 2024
By DBV Technologies S.A. · Via GlobeNewswire · May 16, 2024
DBV Technologies to Participate in Upcoming Investor Conferences
Montrouge, France, May 9, 2024
By DBV Technologies S.A. · Via GlobeNewswire · May 9, 2024
DBV Technologies Reports First Quarter 2024 Financial Results and Business Update
Montrouge, France, May 7, 2024
By DBV Technologies S.A. · Via GlobeNewswire · May 7, 2024
Combined General Meeting of May 16, 2024
Châtillon, France, April 25, 2024
By DBV Technologies S.A. · Via GlobeNewswire · April 25, 2024
Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024
Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024
By DBV Technologies S.A. · Via GlobeNewswire · April 4, 2024
DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document
Montrouge, France, March 8, 2024
By DBV Technologies S.A. · Via GlobeNewswire · March 8, 2024
DBV Technologies Reports Full Year 2023 Financial Results and Business Update
Montrouge, France, March 7, 2024
By DBV Technologies S.A. · Via GlobeNewswire · March 7, 2024
DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024
Montrouge, France, March 4, 2024
By DBV Technologies S.A. · Via GlobeNewswire · March 4, 2024
DBV Technologies to Participate in Upcoming AAAAI 2024 Congress
Montrouge, France, February 20 2024
By DBV Technologies S.A. · Via GlobeNewswire · February 20, 2024
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
AMF Regulated InformationMontrouge, France, January 16, 2024
By DBV Technologies S.A. · Via GlobeNewswire · January 16, 2024
Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2023
Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2023
By DBV Technologies S.A. · Via GlobeNewswire · December 4, 2023
DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers
Montrouge, France, November 9, 2023
By DBV Technologies S.A. · Via GlobeNewswire · November 9, 2023
Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2023
Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2023
By DBV Technologies S.A. · Via GlobeNewswire · November 6, 2023
DBV Technologies to Present New Data at ACAAI 2023
Montrouge, France, November 2, 2023
By DBV Technologies S.A. · Via GlobeNewswire · November 2, 2023
DBV Technologies Receives Requested Feedback from FDA on Protocol Design Elements for COMFORT Safety Studies and Reports Third Quarter 2023 Financial Results
Montrouge, France, October 31, 2023
By DBV Technologies S.A. · Via GlobeNewswire · October 31, 2023
DBV Technologies to Report Third Quarter 2023 Financial Results and Business Update
Montrouge, France, October 27, 2023
By DBV Technologies S.A. · Via GlobeNewswire · October 27, 2023
DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer
Montrouge, France, October 16, 2023
By DBV Technologies S.A. · Via GlobeNewswire · October 16, 2023
Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2023
Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2023
By DBV Technologies S.A. · Via GlobeNewswire · October 5, 2023
DBV Technologies to Participate in Upcoming Investor Conference
Montrouge, France, September 5, 2023
By DBV Technologies S.A. · Via GlobeNewswire · September 5, 2023
DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results
Montrouge, France, July 31, 2023
By DBV Technologies S.A. · Via GlobeNewswire · July 31, 2023
DBV Technologies to Report First Half 2023 Financial Results and Provide a Corporate Update
Montrouge, France, July 25, 2023
By DBV Technologies S.A. · Via GlobeNewswire · July 25, 2023
Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2023
By DBV Technologies S.A. · Via GlobeNewswire · July 19, 2023
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
AMF Regulated InformationMontrouge, France, July 10, 2023
By DBV Technologies S.A. · Via GlobeNewswire · July 10, 2023
Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2023
By DBV Technologies S.A. · Via GlobeNewswire · June 16, 2023
DBV Technologies to Participate in Upcoming EAACI Congress 2023
Montrouge, France, June 8, 2023
By DBV Technologies S.A. · Via GlobeNewswire · June 8, 2023
DBV Technologies to Participate in Upcoming Investor Conference
Montrouge, France, June 06, 2023
By DBV Technologies S.A. · Via GlobeNewswire · June 6, 2023
DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin™ Peanut in Toddlers
Montrouge, France, May 10, 2023
By DBV Technologies S.A. · Via GlobeNewswire · May 10, 2023
DBV Technologies to Participate in Upcoming Investor Conference
Montrouge, France, May 9, 2023
By DBV Technologies S.A. · Via GlobeNewswire · May 9, 2023
DBV Technologies Reports First Quarter 2023 Financial Results
Montrouge, France, May 4, 2023
By DBV Technologies S.A. · Via GlobeNewswire · May 4, 2023
DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDA
Montrouge, France, April 19, 2023
By DBV Technologies S.A. · Via GlobeNewswire · April 19, 2023
DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General Meeting
Montrouge, France, April 12, 2023
By DBV Technologies S.A. · Via GlobeNewswire · April 12, 2023
Ordinary and Extraordinary General Meeting of April 12, 2023
Montrouge, France, March 24, 2023
By DBV Technologies S.A. · Via GlobeNewswire · March 24, 2023
DBV Technologies Update
Montrouge, France, March 13, 2023
By DBV Technologies S.A. · Via GlobeNewswire · March 13, 2023
DBV Technologies Announces First Patient Screened in VITESSE Phase 3 Clinical Trial in Peanut-Allergic Children 4 – 7 Years Old
Montrouge, France, March 7, 2023
By DBV Technologies S.A. · Via GlobeNewswire · March 7, 2023
DBV Technologies announces filing of 2022 Annual Report on Form 10-K and 2022 Universal Registration Document
Montrouge, France, March 2, 2023
By DBV Technologies S.A. · Via GlobeNewswire · March 2, 2023
DBV Technologies Reports Full Year 2022 Financial Results and Business Update
Montrouge, France, March 2, 2023
By DBV Technologies S.A. · Via GlobeNewswire · March 2, 2023
DBV Technologies to Report Full Year 2022 Financial Results and Business Updates on March 2, 2023
Montrouge, France, February 27, 2023
By DBV Technologies S.A. · Via GlobeNewswire · February 27, 2023
DBV Technologies to Participate in Upcoming AAAAI 2023 Congress
Montrouge, France, February 21, 2023
By DBV Technologies S.A. · Via GlobeNewswire · February 21, 2023
DBV Technologies to Participate in Upcoming Investor Conference
Montrouge, France, February 10, 2023
By DBV Technologies S.A. · Via GlobeNewswire · February 10, 2023
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
AMF Regulated InformationMontrouge, France, January 23, 2023
By DBV Technologies S.A. · Via GlobeNewswire · January 23, 2023
Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2022
By DBV Technologies S.A. · Via GlobeNewswire · January 4, 2023
DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial
Montrouge, France, December 23, 2022
By DBV Technologies S.A. · Via GlobeNewswire · December 23, 2022
Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2022
By DBV Technologies S.A. · Via GlobeNewswire · December 8, 2022
DBV Technologies to Participate in Upcoming Investor Conference
Montrouge, France, November 22, 2022
By DBV Technologies S.A. · Via GlobeNewswire · November 22, 2022
DBV Technologies to Highlight New Clinical Data at ACAAI 2022
Montrouge, France, November 9, 2022
By DBV Technologies S.A. · Via GlobeNewswire · November 9, 2022
DBV Technologies Reports Third Quarter Financial Results and Business Update
Montrouge, France, November 3, 2022
By DBV Technologies S.A. · Via GlobeNewswire · November 3, 2022
DBV Technologies to Report Third Quarter 2022 Financial Results and Provide a Business Update
Montrouge, France, October 31, 2022
By DBV Technologies S.A. · Via GlobeNewswire · October 31, 2022
Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2022
Monthly information regarding the total number of voting rights and
By DBV Technologies S.A. · Via GlobeNewswire · October 20, 2022
DBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointment of Daniele Guyot-Caparros to Board of Directors
Montrouge, France, October 3, 2022
By DBV Technologies S.A. · Via GlobeNewswire · October 3, 2022
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
AMF REGULATED INFORMATIONMontrouge, France, July 27, 2022
By DBV Technologies S.A. · Via GlobeNewswire · July 27, 2022